Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.75 |
| ▸ | TTPA | P49638 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628454 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL21999363 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| (+)-Alpha-Tocopheryl Succinate SCHEMBL29409614 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| (+)-Alpha-Tocopheryl Succinate SCHEMBL29903398 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| (+)-Alpha-Tocopheryl Succinate SCHEMBL12628147 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| (+)-Alpha-Tocopheryl Succinate SCHEMBL2162349 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| (+)-Alpha-Tocopheryl Succinate SCHEMBL134422 | 1.00 | GSTO1 (1.00) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL13309644 | 0.96 | GSTO1 (0.93) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL12535829 | 0.96 | GSTO1 (0.93) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL22199470 | 0.96 | GSTO1 (0.93) | GSTO1PTPN1MEN1KMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114652813-A | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| CN-107108698-B | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3778622-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3218392-B1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3218392-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | GSTO1 105/4885PTPN1 421/4885MEN1 3462/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | GSTO1 105/4885PTPN1 421/4885MEN1 3462/4885 |
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | GSTO1 105/4885PTPN1 421/4885MEN1 3462/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | GSTO1 105/4885PTPN1 421/4885MEN1 3462/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | GSTO1 105/4885PTPN1 421/4885MEN1 3462/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | GSTO1 105/4885PTPN1 421/4885MEN1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.